甘精胰岛素联合口服降糖药治疗肥胖2型糖尿病患者的疗效观察

The clinical effect of the insulin glargine pins acarbose and/or metformin in treating type 2 diabetes mellitus with obesity

目的观察甘精胰岛素联合阿卡波糖和(或)二甲双胍治疗肥胖T2DM临床疗效。方法 32例肥胖T2DM患者,在注射预混Ins一段时间后血糖控制不理想情况下,改用甘精胰岛素联合阿卡波糖和(或)二甲双胍,疗程3个月,观察治疗前后BP、FPG、HbA_1c、TC、TG、HDL-C、LDL-C、UA、C-P、uAER变化情况,计算HOMA-IR、HOMA-β。结果治疗后BMI、FPG、HOMA-IR低于治疗前,而C-P、HOMA-β高于治疗前(P<0.05)。结论甘精胰岛素联合阿卡波糖和(或)二甲双胍治疗肥胖T2DM,不仅成功控制血糖,且明显改善IR,治疗中无明显体重增加等不良反应。

Objective To observe the clinical effect of the insulin glargine plus acarbose and （or） metformin in treating type 2 diabetes mellitus with obesity. Methods 32 cases of T2DM with obesity underwent the insulin glargine plus acarbose and（or） metformin treatment when their blood glucose could not be controlled ideally by premixed insulin. The course of the treatment is three months. The changes in BP, FPG, HbA1c, TC, TG, HDL-C, LDL-C, UA, C-P and 24-hUAER were observed before and 3 months after the treatment. Results BMI, FPG, HOMA-IR are lower while C-P and HOMA-β were higher after treatment than before treatment （all P〈 0. 05）. Conclusions The application of insulin glargine plus acarbose and（or） metformin for treating the obesity T2DM not only controls the blood glucose, but also improves the status of metabolic disorder, and never results in severe adverse reactions during treatment.